Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 30:15:1429373.
doi: 10.3389/fpsyt.2024.1429373. eCollection 2024.

A narrative exploration of psilocybin's potential in mental health

Huitae Min #  1 , Soon Young Park #  2 , Jisu Park  1   3 , Seongsu Na  1   3 , Hoe-Suk Lee  3 , Taejung Kim  1   4 , Jungyeob Ham  1   2   4 , Young-Tae Park  1   4
Affiliations
Review

A narrative exploration of psilocybin's potential in mental health

Huitae Min et al. Front Psychiatry. .

Abstract

Psilocybin, a psychoactive substance, has recently garnered attention for its high therapeutic potential in psychiatry. In this study, we investigated the multifaceted aspects of psilocybin, highlighting its chemical properties, mechanisms of action, and burgeoning role in psychiatric treatment. Furthermore, we examined the clinical applications and potential therapeutic benefits of psilocybin in the treatment of various mental health disorders, supported by accumulating clinical evidence. This review aims to deepen our understanding of the clinical impact of psilocybin, elucidate its therapeutic value, and propose directions for future research, thereby paving the way for its integration into mainstream psychiatric treatments. Psilocybin has been shown to be safe in clinical trials with manageable side effects. However, additional safety measures are required after this discussion, including dosing protocols, patient monitoring, and distress management strategies.

Keywords: dosing; mental health disorders; psilocybin; psychiatry; psychoactive.

PubMed Disclaimer

Conflict of interest statement

Authors SP and JH were employed by the company NeoCannBio Co., Ltd. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The pathway of biosynthesis of psilocybin.
See this image and copyright information in PMC

References

    1. Rodriguez Arce JM, Winkelman MJ. Psychedelics, sociality, and human evolution. Front Psychol. (2021) 12:729425. doi: 10.3389/fpsyg.2021.729425 - DOI - PMC - PubMed
    1. Lowe H, Toyang N, Steele B, Valentine H, Grant J, Ali A, et al. . The therapeutic potential of psilocybin. Molecules. (2021) 26:2948. doi: 10.3390/molecules26102948 - DOI - PMC - PubMed
    1. Nichols DE. Psilocybin: from ancient magic to modern medicine. J Antibiot (Tokyo). (2020) 73:679–86. doi: 10.1038/s41429-020-0311-8 - DOI - PubMed
    1. Davis AK, Barrett FS, May DG, Cosimano MP, Sepeda ND, Johnson MW, et al. . Effects of psilocybin-assisted therapy on major depressive disorder: A randomized clinical trial. JAMA Psychiatry. (2021) 78:481–9. doi: 10.1001/jamapsychiatry.2020.3285 - DOI - PMC - PubMed
    1. Carhart-Harris R, Giribaldi B, Watts R, Baker-Jones M, Murphy-Beiner A, Murphy R, et al. . Trial of psilocybin versus escitalopram for depression. N Engl J Med. (2021) 384:1402–11. doi: 10.1056/NEJMoa2032994 - DOI - PubMed

LinkOut - more resources